EVYD Technology
Bandar Seri Begawan, BG3122, Brunei
Location status: Recruiting
Location contact
Jane Tey, Msc Immunology
CONTACT
Joshua Lam, MBBS
CONTACT
NCT Number: NCT06810986
This study is conducted to evaluate the effectiveness of Digital therapeutics (DTx) in managing patients with Type 2 Diabetes Mellitus (T2DM) by delivering digital lifestyle interventions through a national health application (BruHealth).
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Not applicable
Bandar Seri Begawan, BG3122, Brunei
Location status: Recruiting
Jane Tey, Msc Immunology
CONTACT
Joshua Lam, MBBS
CONTACT
This study is a single-arm, non-randomised clinical trial designed to evaluate the effectiveness and feasibility of an online management approach to improve glycaemic control in individuals with Type 2 Diabetes Mellitus (T2DM) through a digital lifestyle intervention (named the BALANCE Programme) over a 16-week period. The intervention leverages the Diabetes Mellitus Digital Therapeutics (DM DTx) module within the BruHealth application. Additionally, a Healthcare Professional (HCP) portal is included to facilitate ongoing monitoring and support, ensuring personalized care and real-time interactions between participants and healthcare providers.
In addition, Muslim participants are offered the option of providing information in the DM DTx module about their fasting practices during Ramadan as an opportunistic way of obtaining data on the fasting risk and fasting experience in this cohort.
Primary Objective:
The primary objective is to assess the proportion of participants who experience a reduction in HbA1c levels by at least 0.6% by the end of the 16-week intervention period.
Secondary Objectives:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be enrolled in a 16-week programme with the aim to manage T2DM through lifestyle adjustments. Participants will be given online support by their personal health coach with additional support from a dietitian or clinician in the study if required.
Each participant will receive personalised recommendations for blood glucose monitoring schedule, diet and physical activity. Participants are required to log their blood glucose, diet and physical activity in the BruHealth application. Participants will review their progress with their health coach via video consultation on a regular basis. Additionally, participants will also participate in a structured diabetes self-management education course.
Other names: Lifestyle Intervention
Time frame: 16 weeks
The proportion of participants who achieve at least 0.6% reduction in HbA1c from baseline following a 16-week lifestyle intervention provided by DM DTx
Time frame: 16 weeks
Evaluation of overall changes in HbA1c
Time frame: 16 weeks
Evaluation of overall changes in fasting lipid profile
Time frame: 16 weeks
Evaluation of overall changes in fasting blood glucose
Time frame: 16 weeks
Evaluation of overall changes in BMI
Time frame: 16 weeks
Evaluation of overall changes in waist circumference
Time frame: 16 weeks
Evaluation of participants' feedback of DM DTx through a series of questionnaires completed on end line
Contact information is provided by the study sponsor or research team.
Jane Tey, Msc Immunology
CONTACT
Joshua Lam, MBBS
CONTACT
EVYD Technology
Industry
Phase 2 Research Study for Type 2 Diabetes Mellitus Through Digital Therapeutics
Acronym: DM DTx
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07463209
Autoimmune Diseases, Diabetes (DM)
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07728669
Body Weight, Diabetes Mellitus
Almaty, Kazakhstan
View Trial DetailsNCT06836479
Diabetes Mellitus, Diabetes Mellitus, Type 2
Stanford, California, United States
View Trial DetailsNCT07465224
Diabetes Mellitus, Diabetes Mellitus, Type 2
Chula Vista, California, United States
View Trial Details